The European Commission (EC) has granted marketing authorization for Nulibry (fosdenopterin) for Injection as the first therapy for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A.
The drug is being developed by US biotech BridgeBio Pharma (Nasdaq: BBIO) and Sentynl Therapeutics, a USA-based subsidiary of India’s Zydus Lifesciences (BOM: 532321), whose shares rose more than 3% to 371 rupees by late afternoon trading. BridgeBio edged up 1.5% to $11.11.
MoCD Type A is an ultra-rare and progressive condition known to impact less than 150 patients globally with a median survival of four years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze